Regenxbio (RGNX) Short-term Investments (2015 - 2026)
Regenxbio (RGNX) posted quarterly Short-term Investments of $195.6 million for Q4 2025, up 10.41% year-over-year from $177.2 million in Q4 2024, and down 9.19% quarter-over-quarter from $215.4 million in Q3 2025.
Regenxbio (RGNX) Short-term Investments (2015 - 2026) Analysis & Trends
Regenxbio's Short-term Investments history runs 11 years deep, the most recent figure standing at $195.6 million for Q4 2025.
- In Q4 2025, Short-term Investments rose 10.41% year-over-year to $195.6 million; the TTM figure through Dec 2025 stood at $195.6 million (up 10.41% YoY), while the FY2025 annual figure was $195.6 million, up 10.41% from the prior year.
- Short-term Investments for Q4 2025 stood at $195.6 million, down from $215.4 million in the prior quarter.
- The five-year high for Short-term Investments was $281.6 million in Q2 2022, with the low at $111.5 million in Q3 2021.
- The 5-year median for Short-term Investments is $220.6 million (2024), against an average of $206.8 million.
- The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 139.31% in 2022, then plunged 38.97% in 2025.
- Regenxbio's Short-term Investments stood at $112.2 million in 2021, then jumped by 138.52% to $267.7 million in 2022, then declined by 10.07% to $240.7 million in 2023, then declined by 26.41% to $177.2 million in 2024, then advanced by 10.41% to $195.6 million in 2025.
- Business Quant data shows RGNX's Short-term Investments at $195.6 million in Q4 2025, $215.4 million in Q3 2025, and $243.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.03 Mn |
| Dec 31, 2025 | 195.60 Mn |
| Sep 30, 2025 | 215.40 Mn |
| Jun 30, 2025 | 243.74 Mn |
| Mar 31, 2025 | 137.77 Mn |
| Dec 31, 2024 | 177.16 Mn |
| Sep 30, 2024 | 198.84 Mn |
| Jun 30, 2024 | 232.59 Mn |
| Mar 31, 2024 | 225.73 Mn |
| Dec 31, 2023 | 240.74 Mn |
| Sep 30, 2023 | 248.84 Mn |
| Jun 30, 2023 | 251.48 Mn |
| Mar 31, 2023 | 261.73 Mn |
| Dec 31, 2022 | 267.69 Mn |
| Sep 30, 2022 | 263.87 Mn |
| Jun 30, 2022 | 281.59 Mn |
| Mar 31, 2022 | 202.26 Mn |
| Dec 31, 2021 | 112.23 Mn |
| Sep 30, 2021 | 111.47 Mn |
| Jun 30, 2021 | 117.67 Mn |